Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Antithymocyte Globulin and Cyclosporine Compared With Standard Therapy in Treating Patients With Myelodysplastic Syndrome
This study is currently recruiting patients.
Sponsored by: | Swiss Institute for Applied Cancer Research |
---|---|
Information provided by: | National Cancer Institute (NCI) |
Purpose
RATIONALE: Antithymocyte globulin and cyclosporine may improve blood counts in patients with myelodysplastic syndrome. It is not yet known whether antithymocyte globulin and cyclosporine are more effective than standard therapy for myelodysplastic syndrome.
PURPOSE: Randomized phase III trial to compare the effectiveness of antithymocyte globulin and cyclosporine with that of standard therapy in treating patients who have myelodysplastic syndrome.
Condition | Treatment or Intervention | Phase |
---|---|---|
Refractory Anemia refractory anemia with ringed sideroblasts refractory anemia with excess blasts de novo myelodysplastic syndromes previously treated myelodysplastic syndromes secondary myelodysplastic syndromes |
Drug: anti-thymocyte globulin Drug: cyclosporine Procedure: biological response modifier therapy Procedure: non-specific immune-modulator therapy |
Phase III |
MedlinePlus related topics: Anemia; Bone Marrow Diseases
Study Type: Interventional
Study Design: Treatment
Official Title: Phase III Randomized Study of Antithymocyte Globulin and Cyclosporine Versus Best Supportive Care in Patients With Low or Intermediate Risk Myelodysplastic Syndrome
OBJECTIVES:
OUTLINE: This is a randomized, multicenter study. Patients are stratified by center and risk group.
Patients are randomized to 1 of 2 treatment arms:
PROJECTED ACCRUAL: A total of 84 patients (42 per arm) will be accrued for this study.
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS: Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Cardiovascular:
Other:
PRIOR CONCURRENT THERAPY: Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Location and Contact Information
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |